newsfilter
← Latest News
GlobeNewswire·

Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

OTO-313 Phase 2 trial is fully enrolled ahead of schedule Top-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development